Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11991
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRembach, Alan-
dc.contributor.authorWatt, Andrew D-
dc.contributor.authorWilson, William J-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorBurnham, Samantha C-
dc.contributor.authorEllis, Kathryn A-
dc.contributor.authorMaruff, Paul-
dc.contributor.authorAmes, David-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorMacaulay, S Lance-
dc.contributor.authorBush, Ashley I-
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorDoecke, James D-
dc.date.accessioned2015-05-16T01:37:35Z
dc.date.available2015-05-16T01:37:35Z
dc.date.issued2014-
dc.identifier.citationJournal of Alzheimer's Disease : Jad; 40(1): 95-104en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11991en
dc.description.abstractWe evaluated the utility of longitudinal measures of plasma amyloid-β (Aβ) as a means to identify pre-symptomatic cognitive decline in Alzheimer's disease (AD) when coupled to neuroimaging and neuropsychological parameters.Participants from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study were grouped based upon cognitive change and changes in measurable levels of neocortical amyloid over 36 months. Participants were classified as those who transitioned for cognitive decline and change in neocortical amyloid, those healthy controls that did not transition, and stable AD participants over 36 months.Comparisons of plasma Aβ levels between the transition and non-transitional groups showed Aβ1-42 and the Aβ1-42/Aβ1-40 ratio were significantly decreased at baseline (p = 0.008 and p = 0.002, respectively) and at 18 months (p = 0.003 and p = 0.004, respectively). Both measures of neocortical amyloid and two previously published composite scores validated the creation of the novel transitional grouping (p < 0.0001). In addition Aβn-42 performed well as a longitudinal prognostic indicator of transition toward cognitive decline, with a significant decrease in the transition group at the 18 month time point (p = 0.01).We demonstrated that baseline plasma Aβ1-42 and the Aβ1-42/Aβ1-40 ratio were putative biomarkers indicative of cognitive decline and validated this result using 18 month data. We created a novel transitional grouping and validated this measure using published measures of neocortical amyloid and composite memory scores. These findings suggest that longitudinal plasma Aβ could contribute to a pre-symptomatic biomarker panel for AD.en
dc.language.isoenen
dc.subject.otherAlzheimer's diseaseen
dc.subject.otherPittsburgh compound Ben
dc.subject.otherbiomarkersen
dc.subject.otherdiagnosisen
dc.subject.otherneocortical amyloid burdenen
dc.subject.otherplasma amyloid-βen
dc.subject.otherpositron emission topographyen
dc.subject.otherAgeden
dc.subject.otherAged, 80 and overen
dc.subject.otherAlzheimer Disease.blood.complicationsen
dc.subject.otherAmyloid beta-Peptides.blooden
dc.subject.otherAniline Compounds.diagnostic useen
dc.subject.otherApolipoprotein E4en
dc.subject.otherCognition Disorders.diagnosis.etiologyen
dc.subject.otherCohort Studiesen
dc.subject.otherDisease Progressionen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMental Status Scheduleen
dc.subject.otherMiddle Ageden
dc.subject.otherNeocortex.metabolism.radionuclide imagingen
dc.subject.otherNeuroimagingen
dc.subject.otherNeuropsychological Testsen
dc.subject.otherPositron-Emission Tomographyen
dc.subject.otherThiazoles.diagnostic useen
dc.titlePlasma amyloid-β levels are significantly associated with a transition toward Alzheimer's disease as measured by cognitive decline and change in neocortical amyloid burden.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Alzheimer's disease : JADen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationCSIRO Preventative Health Flagship: Mathematics, Informatics and Statistics, Perth, WA, Australiaen
dc.identifier.affiliationCSIRO Mathematics, Informatics & Statistics, North Ryde, NSW, Australia CSIRO Molecular and Health Technologies, Preventative Health Flagship, Parkville, Victoria, Australia The Australian E-Health Research Centre, Royal Brisbane and Women's Hospital, Herston, QLD, Australiaen
dc.identifier.affiliationCSIRO Molecular and Health Technologies, Preventative Health Flagship, Parkville, Victoria, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australiaen
dc.identifier.affiliationCSIRO Mathematics, Informatics & Statistics, North Ryde, NSW, Australiaen
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Victoria, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia CogState Ltd., Melbourne, Victoria, Australiaen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia Department of Psychiatry, St. George's Hospital, University of Melbourne, Victoria, Australia National Ageing Research Institute, Parkville, Victoria, Australiaen
dc.identifier.affiliationSir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australiaen
dc.identifier.doi10.3233/JAD-131802en
dc.description.pages95-104en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24334723en
dc.contributor.corpauthorAIBL Research Groupen
dc.type.contentTexten
dc.type.austinJournal Articleen
local.name.researcherMasters, Colin L
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.